Reactive astrocytes give neurons less support: implications for Alzheimer's disease

Astrocytes become activated in Alzheimer's disease (AD), contributing to and reinforcing an inflammatory cascade. It is proposed that by transforming from a basal to a reactive state, astrocytes neglect their neurosupportive functions, thus rendering neurons vulnerable to excitotoxicity and oxidative stress. This review considers 3 important astrocytic functions, that when disrupted, can affect neuronal metabolism. These are the uptake of glucose and release of lactate; the uptake of glutamate and release of glutamine; and the uptake of glutathione precursors and release of glutathione. Conditions under which these functions can be manipulated in vitro, as well as examples of possible loss of astrocytic function in AD, are discussed. It is proposed that the targeting of astrocytes with pharmacological agents that are specifically designed to return astrocytes to a quiescent phenotype could represent a fruitful new angle for the therapeutic treatment of AD and other neurodegenerative disorders.

[1]  D. Pow,et al.  Aberrant Expression of the Glutamate Transporter Excitatory Amino Acid Transporter 1 (EAAT1) in Alzheimer's Disease , 2002, The Journal of Neuroscience.

[2]  J. Csernansky,et al.  CSF excitatory amino acids and severity of illness in Alzheimer's disease , 1996, Neurology.

[3]  D. Pow,et al.  Glutamate in some retinal neurons is derived solely from glia , 1994, Neuroscience.

[4]  P. Mallorga,et al.  Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4′-fluorophenyl)-3-(4′phenylphenoxy)propyl])sarcosine , 2003, Neuropharmacology.

[5]  B. O'dowd,et al.  Inhibition of glutamine synthetase activity prevents memory consolidation. , 1996, Brain research. Cognitive brain research.

[6]  P. Schoenknecht,et al.  Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease , 2010, Neurodegenerative Diseases.

[7]  M. Bellesi,et al.  Synaptic localization of GLT‐1a in the rat somatic sensory cortex , 2009, Glia.

[8]  N. Bogdanovic,et al.  The Swedish APP670/671 Alzheimer’s Disease Mutation: The First Evidence for Strikingly Increased Oxidative Injury in the Temporal Inferior Cortex , 2001, Dementia and Geriatric Cognitive Disorders.

[9]  J. Hirrlinger,et al.  Glutathione Pathways in the Brain , 2003, Biological chemistry.

[10]  A. Camm,et al.  Free radicals irreversibly decrease Ca2+ currents in isolated guinea-pig ventricular myocytes. , 1995, European journal of pharmacology.

[11]  C. Rose,et al.  Identifying the direct effects of ammonia on the brain , 2009, Metabolic Brain Disease.

[12]  P. Magistretti,et al.  Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Vannucci,et al.  Glucose transporter proteins in brain: Delivery of glucose to neurons and glia , 1997, Glia.

[14]  N. Rickard,et al.  Complex Roles of Glutamate in the Gibbs—Ng Model of One-trial Aversive Learning in the New-born Chick , 1997, Neuroscience & Biobehavioral Reviews.

[15]  N. Seiler,et al.  Ammonia and Alzheimer’s disease , 2002, Neurochemistry International.

[16]  Molly M Gallogly,et al.  Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. , 2008, Antioxidants & redox signaling.

[17]  Liang Peng,et al.  Energy Metabolism in Astrocytes: High Rate of Oxidative Metabolism and Spatiotemporal Dependence on Glycolysis/Glycogenolysis , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  M. Norenberg,et al.  Astrocytes Protect Neurons from Ammonia Toxicity , 2005, Neurochemical Research.

[19]  M. Gegg,et al.  Co-culture of neurones with glutathione deficient astrocytes leads to increased neuronal susceptibility to nitric oxide and increased glutamate-cysteine ligase activity , 2005, Brain Research.

[20]  J. Wegiel,et al.  Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.

[21]  S. Serres,et al.  Lactate involvement in neuron-glia metabolic interaction: (13)C-NMR spectroscopy contribution. , 2003, Biochimie.

[22]  P. Magistretti,et al.  Modulation of astrocytic metabolic phenotype by proinflammatory cytokines , 2008, Glia.

[23]  Masahiko Watanabe,et al.  Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. , 1997, Science.

[24]  T. Hagen,et al.  Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Neary,et al.  Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[26]  Anthony Windust,et al.  Omega-3 fatty acids, energy substrates, and brain function during aging. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[28]  W. Brück,et al.  Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? , 1999, Archives of neurology.

[29]  D. Dickson,et al.  Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. , 2006, Brain : a journal of neurology.

[30]  D. Butterfield,et al.  An increase in S‐glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach , 2007, Journal of neuroscience research.

[31]  D. Pow,et al.  Inhibition of Müller cell glutamine synthetase rapidly impairs the retinal response to light , 2000, Glia.

[32]  R. Swanson,et al.  Astrocyte glutamate transport: Review of properties, regulation, and physiological functions , 2000, Glia.

[33]  T. Beach,et al.  Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex , 1988, Brain Research.

[34]  Albert Gjedde,et al.  Neuronal–Glial Glucose Oxidation and Glutamatergic–GABAergic Function , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  P. Dodd,et al.  Glutamate–glutamine cycling in Alzheimer's disease , 2007, Neurochemistry International.

[36]  K. Brockmann The expanding phenotype of GLUT1-deficiency syndrome , 2009, Brain and Development.

[37]  E. Masliah,et al.  Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression , 1997, Journal of neuropathology and experimental neurology.

[38]  P. Desjardins,et al.  N-Acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms , 2010, Metabolic Brain Disease.

[39]  C. Fages,et al.  Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type , 1995, Neurochemical Research.

[40]  R. Butterworth,et al.  Neurobiology of ammonia , 2002, Progress in Neurobiology.

[41]  C. Brayne,et al.  Population Variation in Glial Fibrillary Acidic Protein Levels in Brain Ageing: Relationship to Alzheimer-Type Pathology and Dementia , 2009, Dementia and Geriatric Cognitive Disorders.

[42]  M Aschner,et al.  Neuron-astrocyte interactions: implications for cellular energetics and antioxidant levels. , 2000, Neurotoxicology.

[43]  Jeffrey A. Johnson,et al.  The Nrf2–ARE cytoprotective pathway in astrocytes , 2009, Expert Reviews in Molecular Medicine.

[44]  W. Markesbery,et al.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Butterfield Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain , 2004, Brain Research.

[46]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[47]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Fukuyama,et al.  The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia , 2001, European Neurology.

[49]  K. Zilles,et al.  Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  R. Dringen,et al.  Synthesis of the Antioxidant Glutathione in Neurons: Supply by Astrocytes of CysGly as Precursor for Neuronal Glutathione , 1999, The Journal of Neuroscience.

[51]  J. Leiter,et al.  Inhibition of Monocarboxylate Transporter 2 in the Retrotrapezoid Nucleus in Rats: A Test of the Astrocyte–Neuron Lactate-Shuttle Hypothesis , 2008, The Journal of Neuroscience.

[52]  G. Perry,et al.  Alzheimer disease and the role of free radicals in the pathogenesis of the disease. , 2008, CNS & neurological disorders drug targets.

[53]  P. Desjardins,et al.  Direct Evidence for Central Proinflammatory Mechanisms in Rats with Experimental Acute Liver Failure: Protective Effect of Hypothermia , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  P. Crack,et al.  Glutathione peroxidase 1 and a high cellular glutathione concentration are essential for effective organic hydroperoxide detoxification in astrocytes , 2006, Glia.

[55]  P. Maher,et al.  A novel approach to enhancing cellular glutathione levels , 2008, Journal of neurochemistry.

[56]  R. Martins,et al.  Increased Cerebral Glucose‐6‐Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress , 1986, Journal of neurochemistry.

[57]  Nathalie Rouach,et al.  Astroglial Metabolic Networks Sustain Hippocampal Synaptic Transmission , 2008, Science.

[58]  C. Kunsch,et al.  Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. , 2004, Current pharmaceutical design.

[59]  J. Hirrlinger,et al.  Glutathione metabolism in brain , 2000 .

[60]  S. DeKosky,et al.  Expression of differential immune factors in temporal cortex and cerebellum: The role of α‐1‐antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease , 1998, The Journal of comparative neurology.

[61]  Hubert Blain,et al.  Abnormal Substrate Levels That Depend upon Mitochondrial Function in Cerebrospinal Fluid from Alzheimer Patients , 1998, Gerontology.

[62]  N. Bass Review article: the current pharmacological therapies for hepatic encephalopathy , 2007, Alimentary pharmacology & therapeutics.

[63]  E. Benarroch,et al.  Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. , 2005, Mayo Clinic proceedings.

[64]  Angus M. Brown,et al.  Astrocyte glycogen and brain energy metabolism , 2007, Glia.

[65]  P. Ueland,et al.  Cysteamine increases homocysteine export and glutathione content by independent mechanisms in C3H/10T1/2 cells. , 1990, Molecular Pharmacology.

[66]  Sébastien Tilleux,et al.  Down‐regulation of astrocytic GLAST by microglia‐related inflammation is abrogated in dibutyryl cAMP‐differentiated cultures , 2008, Journal of neurochemistry.

[67]  Close Coupling between Astrocytic and Neuronal Metabolisms to Fulfill Anaplerotic and Energy Needs in the Rat Brain , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  S. Robinson Neuronal expression of glutamine synthetase in Alzheimer’s disease indicates a profound impairment of metabolic interactions with astrocytes , 2000, Neurochemistry International.

[69]  N. Cairns,et al.  Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer’s disease brain , 2004, Journal of Neural Transmission.

[70]  G. Dienel,et al.  Astrocytes are poised for lactate trafficking and release from activated brain and for supply of glucose to neurons , 2009, Journal of neurochemistry.

[71]  K. Blennow,et al.  Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.

[72]  S. Kropf,et al.  Consumption of redox energy by glutathione metabolism contributes to hypoxia/ reoxygenation-induced injury in astrocytes , 2006, Molecular and Cellular Biochemistry.

[73]  Daniela Calvetti,et al.  Astrocytes as the glucose shunt for glutamatergic neurons at high activity: an in silico study. , 2009, Journal of neurophysiology.

[74]  R. V. Van Heertum,et al.  Imaging the metabolic footprint of Glut1 deficiency on the brain , 2002, Annals of neurology.

[75]  D. Häussinger,et al.  Ammonia triggers exocytotic release of L‐glutamate from cultured rat astrocytes , 2009, Glia.

[76]  D. Bennett,et al.  Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[77]  B. Winblad,et al.  The Cerebrocortical Areas in Normal Brain Aging and in Alzheimer's Disease: Noticeable Differences in the Lipid Peroxidation Level and in Antioxidant Defense , 2001, Neurochemical Research.

[78]  Pierre J Magistretti,et al.  Brain lactate kinetics: Modeling evidence for neuronal lactate uptake upon activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Benito-León,et al.  Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease , 1998, Journal of Neural Transmission.

[80]  A. Volterra,et al.  Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. , 2007, International review of neurobiology.

[81]  B. McEwen,et al.  Glucose transporter expression in the central nervous system: relationship to synaptic function. , 2004, European journal of pharmacology.

[82]  Won-Ki Kim,et al.  Potentiated glucose deprivation‐induced death of astrocytes after induction of iNOS , 1998, Journal of neuroscience research.

[83]  C. Brayne,et al.  Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain , 2010, Neurobiology of Aging.

[84]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[85]  M. Berría,et al.  Immunochemical and morphometric features of astrocyte reactivity vs. plaque location in Alzheimer's disease. , 2005, Medicina.

[86]  D. Leibfritz,et al.  Sustained hydrogen peroxide stress decreases lactate production by cultured astrocytes , 2009, Journal of neuroscience research.

[87]  M. Norenberg,et al.  Signaling factors in the mechanism of ammonia neurotoxicity , 2009, Metabolic Brain Disease.

[88]  D. Pow,et al.  Neuronal Expression of Splice Variants of “Glial” Glutamate Transporters in Brains Afflicted by Alzheimer’s Disease: Unmasking an Intrinsic Neuronal Property , 2009, Neurochemical Research.

[89]  G. Dienel,et al.  Imaging Brain Activation , 2008, Annals of the New York Academy of Sciences.

[90]  P. Magistretti,et al.  Selective Distribution of Lactate Dehydrogenase Isoenzymes in Neurons and Astrocytes of Human Brain , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[91]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[92]  D. Marshak,et al.  Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe , 1992, Neurobiology of Aging.

[93]  F. Larsen,et al.  The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema , 2009, Metabolic Brain Disease.

[94]  T. Korn,et al.  Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GLAST: a mechanism mediated by tumor necrosis factor‐α , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  D. Butterfield,et al.  The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42 , 2001, Journal of neurochemistry.

[96]  Xiao-Ming Xu,et al.  Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons , 2010, Neurochemistry International.

[97]  B. Kowtharapu,et al.  Expression of Pyruvate Carboxylase in Cultured Oligodendroglial, Microglial and Ependymal Cells , 2009, Neurochemical Research.

[98]  K. Blennow,et al.  Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia , 1999, Journal of Clinical Immunology.

[99]  A. McCall,et al.  Ultrastructural localization of GLUT 1 and GLUT 3 glucose transporters in rat brain , 1997, Journal of neuroscience research.

[100]  S. Robinson,et al.  Neurones express glutamine synthetase when deprived of glutamine or interaction with astrocytes , 2010, Journal of neurochemistry.

[101]  S. Robinson,et al.  Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease , 2001, Journal of neuroscience research.

[102]  A. M. Palmer,et al.  The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease , 1999, Journal of Neural Transmission.

[103]  E. Masliah,et al.  Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype , 1998, Journal of Neuroimmunology.

[104]  E. Masliah,et al.  Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease , 1996 .

[105]  A. Schousboe,et al.  Glutamine in the central nervous system: function and dysfunction. , 2007, Frontiers in bioscience : a journal and virtual library.

[106]  R. Butterworth,et al.  Mitochondrial dysfunction in acute hyperammonemia , 2002, Neurochemistry International.

[107]  E. Benveniste,et al.  Immune function of astrocytes , 2001, Glia.

[108]  R. Branconnier,et al.  Blood ammonia and Alzheimer's disease. , 1986, The American journal of psychiatry.

[109]  Lingyun Wu,et al.  FREE RADICAL GENERATION BY METHYLGLYOXAL IN TISSUES , 2008, Drug metabolism and drug interactions.

[110]  Nick C Fox,et al.  Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease , 2003, Neuroscience Letters.

[111]  W. Markesbery,et al.  Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease , 2001, Neuroscience Letters.

[112]  S. Robinson,et al.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer’s disease , 2006, Journal of Neural Transmission.

[113]  L. Hertz Is Alzheimer's disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells? , 1989, Brain Research Reviews.

[114]  P. Magistretti,et al.  Metabolic compartmentalization in the human cortex and hippocampus: evidence for a cell- and region-specific localization of lactate dehydrogenase 5 and pyruvate dehydrogenase , 2007, BMC Neuroscience.

[115]  Leif Hertz,et al.  Astrocytes: Glutamate producers for neurons , 1999, Journal of neuroscience research.

[116]  L. Felipe Barros,et al.  Why glucose transport in the brain matters for PET , 2005, Trends in Neurosciences.

[117]  R. Issels,et al.  Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. , 1989, Cancer research.

[118]  A. Verkhratsky,et al.  Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease , 2010, Glia.

[119]  E. Tobinick,et al.  Tumour Necrosis Factor Modulation for Treatment of Alzheimer’s Disease , 2009, CNS drugs.